1.Optimal dose of gamma irradiation for the prevention of transfusion-associated graft-versus-host disease.
Dae Won KIM ; Eun Suk KANG ; Hyun Suk CHI ; Won Ki MIN ; Chowl Won SUH
Korean Journal of Blood Transfusion 1993;4(1):67-74
No abstract available.
Graft vs Host Disease*
2.Chronic Cutaneous Graft versus Host Disease Mimicking Warts.
Bo In LEE ; Young Min PARK ; Hyung Ok KIM ; Jun Young LEE
Annals of Dermatology 2015;27(1):90-92
No abstract available.
Graft vs Host Disease*
;
Warts*
3.Acute Cutaneous Graft-Versus-Host Reaction.
Annals of Dermatology 1997;9(2):77-86
Graft-versus-host disease occurs after the administration of foreign immunologically competent cells to an individual who is immunologically compromised. It is a clinical syndrome characterized by cutaneous changes, gastrointestinal dysfunction and liver dysfunction. Cutaneous graft-versus-host reaction is usually the earliest and certainly the most common form of the disease. The diagnosis of graft-versus-host disease is a complex clinicopathologic skill requiring considerable experience. There as yet appears to be no pathognomonic single clinical or histologic feature in the acute phase. In this review article, the definition, immunological aspects and. clinical features of graft-versus-host disease, diagnostic criteria of acute cutaneous graft-versus-host reaction and graft-versus-tumor effect are discussed.
Diagnosis
;
Graft vs Host Disease
;
Liver Diseases
4.Graft-versus-Host Disease: Report of Four Cases.
Jong Yuk YI ; Baik Kee CHO ; Won HOUH ; Chong Won PARK ; Choon Choo KIM
Annals of Dermatology 1989;1(1):21-27
No abstract available.
Graft vs Host Disease*
;
HLA-DR Antigens
5.Acute Graft-versus-Host Disease after Liver Transplantation.
Hyunju JIN ; Hyunho CHO ; Wonjeong KIM ; Jeho MUN ; Margaret SONG ; Hoon Soo KIM ; Byung Soo KIM ; Moon Bum KIM ; Hyun Chang KO
Korean Journal of Dermatology 2014;52(10):761-763
No abstract available.
Graft vs Host Disease*
;
Liver Transplantation*
7.The role of B cells in acute graft-versus-host disease.
Byung Sik CHO ; Nak Gyun CHUNG
Korean Journal of Hematology 2011;46(4):287-288
No abstract available.
B-Lymphocytes
;
Graft vs Host Disease
10.New Strategies for Overcoming Limitations of Mesenchymal Stem Cell-Based Immune Modulation.
International Journal of Stem Cells 2015;8(1):54-68
Mesenchymal stem cells (MSCs) have rapidly been applied in a broad field of immune-mediated disorders since the first successful clinical use of MSCs for treatment of graft-versus-host disease. Despite the lack of supporting data, expectations that MSCs could potentially treat most inflammatory conditions led to rushed application and development of commercialized products. Today, both pre-clinical and clinical studies present mixed results for MSC therapy and the discrepancy between expected and actual efficacy of MSCs in various diseases has evoked a sense of discouragement. Therefore, we believe that MSC therapy may now be at a critical milestone for re-evaluation and re-consideration. In this review, we summarize the current status of MSC-based clinical trials and focus on the discrepancy between expected and actual outcome of MSC therapy from bench to bedside. Importantly, we discuss the underlying limitations of MSCs and suggest a new guideline for MSC therapy in hopes of improving their therapeutic efficacy.
Graft vs Host Disease
;
Hope
;
Mesenchymal Stromal Cells
Result Analysis
Print
Save
E-mail